3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Conditions
Neoplasms
1
Interventions
Gemcitabine
26
Paclitaxel
24
pembrolizumab
23
Carboplatin
22
Bevacizumab
18
Radiotherapy
16
Oxaliplatin
16
Erlotinib Hydrochloride
16
Nivolumab
15
Cisplatin
14
Capecitabine
14
Fluorouracil
13
Trastuzumab
12
Docetaxel
12
atezolizumab
11
Magnetic Resonance Spectroscopy
11
Leucovorin
11
Cyclophosphamide
11
Irinotecan
10
Ipilimumab
10
Vemurafenib
9
Everolimus
9
Cetuximab
9
cabozantinib
8
Radiosurgery
8
Afatinib
8
130-nm albumin-bound paclitaxel
8
trametinib
7
lenvatinib
7
durvalumab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Human Papillomavirus Recombinant Vaccine nonavalent
×
Tumor-Agnostic
×
Clear all
NCT06658405
2026-03-18
HPV2
Centre Oscar Lambret
Phase 2
Recruiting
85 enrolled